Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8781880 | 0.83 | CYP1A2 (0.40) | ADORA1ALDH1A1HSD17B10TYRRAB9A | |
| SCHEMBL2297576 | 0.74 | ADORA1 (0.48) | ADORA1ADORA2ALMNATYRNPC1 | |
| SCHEMBL4337068 | 0.71 | PAX3 (0.39) | ADORA1LMNAALDH1A1HSD17B10TSHR | |
| SCHEMBL16316425 | 0.71 | ADORA1 (0.56) | ADORA1ADORA2ALMNAALDH1A1HSD17B10 | |
| SCHEMBL25322413 | 0.69 | GSK3B (0.37) | ALDH1A1TSHRNOS1NPC1RAB9A | |
| SCHEMBL10995388 | 0.66 | ADORA1 (0.42) | ADORA1ADORA2ALMNAALDH1A1HSD17B10 | |
| SCHEMBL4777464 | 0.65 | ADORA1 (0.41) | ADORA1ADORA2ALMNAALDH1A1HSD17B10 | |
| SCHEMBL6483424 | 0.65 | ALDH1A1 (0.42) | ADORA1ADORA2ALMNAALDH1A1HSD17B10 | |
| SCHEMBL30590049 | 0.65 | ADORA1 (0.41) | ADORA1ADORA2ALMNAALDH1A1HSD17B10 | |
| SCHEMBL4777463 | 0.64 | GDA (0.42) | ADORA1ADORA2ALMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | US | claimed |
| EP-2862868-B1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO CO LTD (JP) | 2020-04-08 | — | — | EP | claimed |
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| US-9738681-B2 | Intermediate for production of nucleoside analog and method for producing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-22 | — | — | US | claimed |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-03-10 | — | — | US | claimed |
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2862868-A1 | INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | claimed |
| US-8957201-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | claimed |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | claimed |
| US-7816333-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | claimed |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-11 | — | — | US | claimed |
| US-7335765-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-26 | — | — | US | claimed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | claimed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | claimed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | claimed |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY, LIMITED (JP) | 2002-10-10 | — | — | US | claimed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | claimed |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-1201678-A1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | Sankyo Company, Limited (JP) | 2002-05-02 | — | — | EP | disclosed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152132-A1 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | ADORA1 874/4885ADORA2A 1679/4885LMNA 887/4885 |
| US-20160068561-A9 | Intermediate for Production of Nucleoside Analog and Method for Producing the Same | RNGTT, NSUN2, RNMT | ADORA1 874/4885ADORA2A 1679/4885LMNA 887/4885 |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | ADORA1 198/4885ADORA2A 204/4885LMNA 764/4885 |
| US-20020147332-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | ADORA1 35/4885ADORA2A 136/4885LMNA 2615/4885 |
| US-20090149404-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | ADORA1 198/4885ADORA2A 204/4885LMNA 764/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | ADORA1 35/4885ADORA2A 136/4885LMNA 2615/4885 |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | PFAS, ENPP1, NAAA | ADORA1 2740/4885ADORA2A 2111/4885LMNA 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.